CA-074: Selective Cathepsin B Inhibitor for Cancer Metastasis Research

Executive Summary: CA-074 is a potent, selective inhibitor of cathepsin B (Ki = 2–5 nM), showing >10,000-fold selectivity over cathepsins H and L (Ki = 40–200 μM) (APExBIO product page). Chemical inhibition of cathepsin B by CA-074 protects cells from necroptosis, highlighting its role in regulated cell death (Liu et al. 2024). In vivo, CA-074 reduces bone metastasis in 4T1.2 breast cancer models without affecting primary tumor growth. The compound also suppresses neurotoxicity via microglial modulation and shifts immune responses from Th-2 to Th-1, lowering IgE and IgG1 levels. CA-074 demonstrates high solubility in DMSO, ethanol, and water (with ultrasonic assistance), with minimal cytotoxicity at 10 mM in cell culture (APExBIO).

Biological Rationale

Cathepsin B is a lysosomal cysteine protease involved in proteolytic pathways that regulate cell death, immune responses, and metastasis (Liu et al. 2024). During necroptosis, MLKL polymerization triggers lysosomal membrane permeabilization (LMP), leading to cytosolic release of cathepsins, with cathepsin B acting as a critical effector of cell death. In oncology, cathepsin B promotes tumor invasion and metastasis by degrading extracellular matrix components. In neurobiology, it mediates neuronal death following microglial activation by amyloid-beta (Abeta42). The immune system utilizes cathepsin B in antigen processing and T cell response modulation (Translational Frontiers).

Mechanism of Action of CA-074, Cathepsin B inhibitor

CA-074 is a small molecule with the chemical name (2S)-1-[(2S,3S)-3-methyl-2-[[(3S)-3-(propylcarbamoyl)oxirane-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carboxylic acid, molecular weight 383.44 g/mol (APExBIO). It binds to the active site of cathepsin B and inhibits proteolytic activity with high selectivity. The compound has negligible inhibitory activity against related cathepsins H and L, as confirmed by binding assays (Ki > 40 µM for H/L). By blocking cathepsin B, CA-074 prevents downstream proteolytic cascades that promote tumor metastasis, lysosome-mediated cell death, and Th-2 immune polarization (Targeting Cathepsin B). This mechanism interrupts the execution phase of necroptosis, as demonstrated by protection from MLKL-induced lysosomal damage in vitro.

Evidence & Benchmarks

• CA-074 inhibits cathepsin B with Ki of 2–5 nM, showing >10,000-fold selectivity over cathepsins H and L (Ki = 40–200 μM) (APExBIO).
• Chemical inhibition of cathepsin B by CA-074 protects cells from necroptosis triggered by MLKL polymerization and lysosomal membrane permeabilization (Liu et al. 2024).
• In a 4T1.2 breast cancer mouse model, CA-074 (50 mg/kg i.p.) reduced bone metastasis without affecting primary tumor growth (APExBIO).
• CA-074 mitigates neurotoxicity by suppressing Abeta42-activated microglia-mediated neuronal cell death (Strategic Inhibition).
• In immune assays, CA-074 shifts T helper cell activity from Th-2 to Th-1, reducing IgE and IgG1 production (Unlocking Cathepsin B Inhibition).
• Compound is soluble in DMSO (>19.17 mg/mL), ethanol (>31.3 mg/mL), and water (>5.91 mg/mL with ultrasonic assistance) (APExBIO).
• Shows negligible cytotoxicity in cell culture at 10 mM (APExBIO).

This article extends Targeting Cathepsin B by providing updated mechanistic details on MLKL-driven necroptosis and in vivo benchmarks, and clarifies experimental boundaries compared to Optimizing Cell Death Assays, which focuses on workflow-specific tips. It also updates Translational Frontiers by integrating the latest peer-reviewed necroptosis evidence.

Applications, Limits & Misconceptions

CA-074 is widely used in preclinical research to dissect cathepsin B's role in cancer metastasis, neuronal injury, and immune modulation. It enables precise inhibition of cathepsin B in vitro and in vivo, facilitating mechanistic studies of proteolytic cascades and regulated cell death. The compound is compatible with cell culture and animal models due to its low cytotoxicity and high solubility.

Common Pitfalls or Misconceptions

• CA-074 is not a pan-cathepsin inhibitor; it does not significantly inhibit cathepsin H or L at relevant concentrations (APExBIO).
• It is not effective against serine or aspartic proteases.
• In vivo efficacy is established primarily in metastasis models; effects on primary tumor growth are minimal.
• Solubility in water requires ultrasonic assistance; incomplete dissolution may affect dosing accuracy.
• Long-term solution storage is not recommended; use fresh solutions for reproducibility.

Workflow Integration & Parameters

For cell-based assays, CA-074 is typically used at concentrations up to 10 mM, exhibiting negligible cytotoxicity. For in vivo studies, intraperitoneal injection at 50 mg/kg in mouse models has shown efficacy in reducing bone metastasis. The compound is soluble in DMSO (>19.17 mg/mL), ethanol (>31.3 mg/mL), and water (>5.91 mg/mL with ultrasonic assistance). Storage at -20°C is recommended; solutions should be prepared fresh before use. CA-074 is supplied by APExBIO as SKU A1926. For more on optimizing assay design using this inhibitor, see Optimizing Cell Death Assays, which focuses on practical protocols.

Conclusion & Outlook

CA-074, Cathepsin B inhibitor, is a gold-standard reagent for selective inhibition of cathepsin B in cancer, neurobiology, and immunology research (product page). Its nanomolar potency and high selectivity enable precise interrogation of cathepsin B-mediated pathways, particularly in the context of MLKL-driven necroptosis and metastasis. Recent peer-reviewed findings confirm that chemical inhibition of cathepsin B can block necroptotic cell death, providing new avenues for translational research (Liu et al. 2024). As understanding of cathepsin B's role in health and disease evolves, CA-074 will remain an essential tool in experimental and preclinical workflows.